View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 10, 2021

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients.

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients.

The trial initiation comes after approval from the Human Research Ethics Committee (HREC) and clearance of Clinical Trial Notification (CTN) from the Australian Therapeutic Goods Administration (TGA).

An antibody-based radioimmunoconjugate or molecularly targeted radiotherapy (MTR), TLX591 targets prostate-specific membrane antigen (PSMA).

PSMA is a cancer target that is frequently found in metastatic prostate cancer patients.

The international, multi-centre randomised controlled Phase III trial will have around 390 subjects selected with the help of 68Ga-PSMA imaging with TLX591- companion diagnostics (CDx), Illuccix.

A lead investigational product of Telix, Illuccix is intended for prostate cancer imaging. It is currently under the TGA’s priority evaluation.

The trial subjects will be PSMA-expressing mCRPC patients whose disease had progressed after receiving a novel androgen axis drug (NAAD) as the previous treatment.

The trial will assess standard of care (SOC) therapy plus TLX591 versus SOC therapy alone.

Radiographic progression-free survival will form the trial’s primary endpoint while secondary endpoints will be overall survival and quality-of-life assessment.

Telix Pharmaceuticals CEO Dr Christian Behrenbruch said: “ProstACT builds on a significant body of clinical data for TLX591, which to date has been studied in over 200 patients with advanced prostate cancer, across five previous studies.

“TLX591 has demonstrated promising and competitive clinical potential that we believe warrants further confirmation in this second-line disease setting.”

The company initiated the trial sites in Australia and plans to gradually include more sites across the globe during the second half of this year on obtaining necessary approvals.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU